PE/Cyanine7 anti-mouse CD25 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

IL-2-dependent cytolytic mouse T-cell clone B6.1

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation^1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors^1-4, growth inhibition of IL-2-dependent T-cell lines^1-4, in vivo depletion of CD25⁺CD4⁺ Treg cells^5-8,10, and immunohistochemical staining of acetone-fixed frozen sections². PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
9. León-Ponte M, et al. 2007. Blood 109:3139.
10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed

Product Citations

1. Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed
2. Gruber R, et al. 2014. J Neurosci. 34:16320. PubMed
3. Kawabe T, et al. 2020. Nat Commun. 2.795833333. PubMed
4. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
5. Fu Z, et al. 2019. Cell Rep. 28:159. PubMed
6. Andrade MS, et al. 2022. JCI Insight. 7:. PubMed
7. Prasad M, et al. 2020. Cell Mol Immunol. . PubMed
8. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
9. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
10. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
11. Elisabeth Schrumpf, Xiaojun Jiang 2017. Physiol Rep. 10.14814/phy2.13117. PubMed
12. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
13. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
14. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
15. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
16. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
17. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
18. Marfil-Garza BA, et al. 2022. Am J Transplant. 22:1101. PubMed
19. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
20. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
21. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
22. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
23. Martinikova AS, et al. 2020. Cells. 9:00. PubMed
24. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
25. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
26. Xiong Y, et al. 2018. Int J Clin Exp Pathol. 3.803472222. PubMed
27. Trompette A, et al. 2022. Mucosal Immunol. :. PubMed
28. Benechet AP, et al. 2019. Nature. 574:200. PubMed
29. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
30. Ng SS, et al. 2020. Nat Immunol. 21:1205. PubMed
31. Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed
32. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
33. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
34. De Simone G, et al. 2021. Immunity. :. PubMed
35. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
36. Sinclair LV, et al. 2020. Immunometabolism. 2:e200029. PubMed
37. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
38. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
39. Lindner J, et al. 2014. J Immunol. 192:4483. PubMed
40. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
41. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
42. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
43. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
44. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
45. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
46. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
47. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
48. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
49. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
50. Zeis P, et al. 2020. Immunity. 53:775. PubMed
51. Moreau H, et al. 2015. Proc Natl Acad Sci U S A. 112: 12151-12156. PubMed
52. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
53. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
54. Li D, et al. 2020. Immunohorizons. 0.661805556. PubMed
55. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
56. Rao R, et al. 2015. Toxicol Sci. 144:284. PubMed
57. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
58. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
59. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
60. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
61. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
62. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
63. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
64. Liu A, et al. 2022. Front Cell Infect Microbiol. 12:960208. PubMed
65. Zaiss M, et al. 2015. Immunity. 43: 998-1010. PubMed
66. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
67. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
68. Nabekura T, et al. 2020. Immunity. 96:52. PubMed

RRID

AB_312864 (BioLegend Cat. No. 102015)
AB_312865 (BioLegend Cat. No. 102016)

Antigen Details

Structure

Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD

Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function

IL-2 receptor

Ligand/Receptor

IL-2

Cell Type

B cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, Cytokine/Chemokine Receptors

Antigen References

1. Taniguchi T, et al. 1993. Cell 73:5-8.
2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
3. Read S, et al. 2000. J Exp Med. 192:295-302.
4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.

Gene ID

16184 View all products for this Gene ID

UniProt

View information about CD25 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis